PDS Biotechnology (NASDAQ:PDSB) Cut to "Sell" at Wall Street Zen

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday.

Separately, HC Wainwright reissued a "buy" rating and set a $13.00 target price on shares of PDS Biotechnology in a report on Wednesday.

PDS Biotechnology Stock Performance

Shares of NASDAQ:PDSB traded down $0.04 during mid-day trading on Friday, reaching $1.75. The company had a trading volume of 327,198 shares, compared to its average volume of 495,109. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. The firm has a market cap of $79.99 million, a price-to-earnings ratio of -1.51 and a beta of 1.27. The company's 50-day moving average price is $1.34 and its 200-day moving average price is $1.46. PDS Biotechnology has a one year low of $0.85 and a one year high of $4.42.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. As a group, equities research analysts anticipate that PDS Biotechnology will post -1.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PDSB. Raymond James Financial Inc. bought a new position in shares of PDS Biotechnology during the fourth quarter valued at about $26,000. Jane Street Group LLC bought a new position in PDS Biotechnology in the fourth quarter worth about $58,000. Marshall Wace LLP increased its stake in shares of PDS Biotechnology by 38.4% during the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company's stock valued at $64,000 after purchasing an additional 10,837 shares in the last quarter. Virtu Financial LLC bought a new position in shares of PDS Biotechnology during the fourth quarter valued at approximately $89,000. Finally, Two Sigma Investments LP increased its stake in shares of PDS Biotechnology by 273.5% during the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company's stock valued at $107,000 after purchasing an additional 48,132 shares in the last quarter. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.